Palm oil tocotrienol rich fraction reduces extracellular matrix production by inhibiting transforming growth factor-β1 in human intestinal fibroblasts

Clinical Nutrition

Volumn 30, Issue 6, 2011, Pages 858-864

  Luna, Jeroni ^a   Masamunt, Maria Carme ^a   Llach, Josep ^a   Delgado, Salvadora ^a   Sans, Miquel ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Fibroblasts; Inflammatory bowel disease; Tocotrienol rich fraction

Indexed keywords

ALPHA TOCOTRIENOL; INTERSTITIAL COLLAGENASE; PALM OIL; PROCOLLAGEN; PROCOLLAGEN 1; PROCOLLAGEN 3; SCLEROPROTEIN; SMAD3 PROTEIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOCOMIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFECT; DRUG MECHANISM; EXTRACELLULAR MATRIX; FIBROBLAST CULTURE; FIBROGENESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE CELL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; COLLAGEN TYPE I; COLLAGEN TYPE III; CROHN DISEASE; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; INTESTINES; MATRIX METALLOPROTEINASE 3; PLANT OILS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TOCOTRIENOLS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 82255162905     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2011.07.001     Document Type: Article

References (34)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115(1):182-205.
2. Korzenik J.R., Podolsky D.K. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 2006, 5:197-209.
3. Rieder F., Fiocchi C. Intestinal fibrosis in IBD-a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol 2009, 6:228-235.
4. Burke J.P., Mulsow J.J., O'Keane C. Fibrogenesis in Crohn's disease. Am J Gastroenterol 2007, 102:439-448.
5. McKaig B.C., Hughes K., Tighe P.J., Mahida Y.R. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 2002, 282:C172-C182.
6. Leask A., Abraham D.J. TGF-beta signalling and the fibrotic response. FASEB J 2004, 18:816-827.
7. di Mola F.F., Friess H., Scheuren A., Di Sebastiano P., Graber H., Egger B., et al. Transforming growth factor-betas and their signalling receptors are coexpressed in Crohn's disease. Ann Surg 1999, 229:67-75.
8. Di Sabatino A., Pender S.L.F., Jackson C.L., Prothero J.D., Gordon J.N., Picariello L., et al. Functional modulation of Crohn's disease myofibroblasts by anti-TNF antibodies. Gastroenterology 2007, 133:137-149.
9. Rieder F., Fiocchi C. Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol 2008, 24:462-468.
10. Nesaretnam K., Guthrie N., Chambers A.F., Carroll K.K. Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids 1995, 30:1139-1143.
11. Sen C.K., Khanna S., Roy S., Packer L. Molecular basis of vitamin E action. Tocotrienol potently inhibits glutamate-induced pp60 (c-Src) kinase activation and death of HT4 neuronal cells. J Biol Chem 2000, 275:13049-13055.
12. Qureshi A.A., Qureshi N., Wright J.J., Shen Z., Kramer G., Gapor A., et al. Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). Am J Clin Nutr 1991, 53:1021S-1026S.
13. Wada S., Satomi Y., Murakoshi M., Noguchi N., Yoshikawa T., Nishino H. Tumor suppressive effects of tocotrienol in vivo and in vitro. Cancer Lett 2005, 229:181-191.
14. Yu W., Simmons-Menchaca M., Gapor A., Sanders B.G., Kline K. Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. Nutr Cancer 1999, 33:26-32.
15. Rickmann M., Vaquero E.C., Malagelada J.R., Molero X. Tocotrienols induce apoptosis and autophagy in rat pancreatic stellate cells through the mitochondrial death pathway. Gastroenterology 2007, 132:2518-2532.
16. Luna J., Masamunt M.C., Rickmann M., Mora R., España C., Delgado S., et al. Tocotrienols have potent anti-fibrogenic effects in human intestinal fibroblasts. Inflamm Bowel Dis 2011, 17:732-741.
17. Strong S.A., Pizarro T.T., Klein J.S., Cominelli F., Fiocchi C. Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells. Gastroenterology 1998, 114:1244-1256.
18. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998, 67:753-791.
19. Roberts A.B., Russo A., Felici A., Flanders K.C. Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta. Ann N Y Acad Sci 2003, 995:1-10.
20. Latella G., Vetuschi A., Sferra R., Zanninelli G., D'Angelo A., Catitti V., et al. Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis. Eur J Clin Invest 2009, 39(2):145-156.
21. Boscoboinik D., Szewczyk A., Hensey C., Azzi A. Inhibition of cell proliferation by α-tocopherol. Role of protein kinase C. J Biol Chem 1991, 266:6188-6194.
22. Ricciarelli R., Tasinato A., Clement S., Ozer N.K., Boscoboinik D., Azzi A. Alpha-tocopherol specifically inactivates cellular protein kinase C alpha by changing its phosphorylation state. Biochem J 1998, 334:243-249.
23. Lasserre R., Guo X.-J., Conchonaud F., Hamon Y., Hawchar O., Bernard A.M., et al. Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol 2008, 4:538-547.
24. Royer M.C., Lemaire-Ewing S., Desrumaux C., Monier S., Pais de Barros J.P., Athias A., et al. 7-ketocholesterol incorporation into sphingolipid/cholesterol-enriched (lipid raft) domains is impaired by Vitamin E: a specific role for alpha-tocopherol with consequences on cell death. J Biol Chem 2009, 284:15826-15834.
25. Lawrance I.C., Wu F., Leite A.Z., Willis J., West G.A., Fiocchi C., et al. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology 2003, 125:1750-1761.
26. Gunther U., Schuppan D., Bauer M., Matthes H., Stallmach A., Schmitt-Gräff A., et al. Fibrogenesis and fibrolysis in collagenous colitis. Patterns of procollagen types I and IV, matrix-metalloproteinase-1 and -13 and TIMP-1 gene expression. Am J Pathol 1999, 155:493-503.
27. Mimura T., Bateman A.C., Lee R.L., Johnson P.A., McDonald P.J., Talbot I.C., et al. Up-regulation of collagen and tissue inhibitors of matrix metalloproteinase in colonic diverticular disease. Dis Colon Rectum 2004, 47:371-378.
28. Di Sabatino A., Jackson C.L., Pickard K.M. Transforming growth factor β signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 2009, 58:777-789.
29. Ricciarelli R., Maroni P., Ozer N., Zingg J.M., Azzi A. Age-dependent increase of collagenase expression can be reduced by alpha-tocopherol via protein kinase C inhibition. Free Radic Biol Med 1999, 27:729-737.
30. Mauch S., Kolb C., Kolb B., Sadowski T., Sedlacek R. Matrix metalloproteinase-19 is expressed in myeloid cells in an adhesion-dependent manner and associates with the cell surface. J Immunol 2002, 168:1244-1251.
31. Graham M.F., Diegelmann R.F., Elson C.O., Lindblad W.J., Gotschalk N., Gay S., et al. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology 1988, 94:257-265.
32. Rieder F., Brenmoehl J., Leeb S., Schölmerich J., Rogler G. Wound healing and fibrosis in intestinal disease. Gut 2007, 56:130-139.
33. Verrechia F., Chu M.L., Mauviel A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 2001, 276:17058-17062.
34. Singh U., Devaraj S., Vitamin E. inflammation and atherosclerosis. Vitam Horm 2007, 76:519-549.